Associated risk factors for extended length of stay following anterior cervical discectomy and fusion for cervical spondylotic myelopathy.


Journal

Clinical neurology and neurosurgery
ISSN: 1872-6968
Titre abrégé: Clin Neurol Neurosurg
Pays: Netherlands
ID NLM: 7502039

Informations de publication

Date de publication:
08 2020
Historique:
received: 24 03 2020
revised: 28 04 2020
accepted: 29 04 2020
pubmed: 20 5 2020
medline: 16 6 2021
entrez: 20 5 2020
Statut: ppublish

Résumé

There is a paucity of literature describing the predictors associated with extended length of hospital stay (LOS) for patients undergoing anterior cervical discectomy and fusion (ACDF) for cervical spondylotic myelopathy. The aim of this study was to identify the patient- and hospital-level factors associated with extended LOS for patients with cervical spondylotic myelopathy undergoing ACDF. The National Inpatient Sample database was queried to identify patients with a diagnosis of cervical spondylotic myelopathy undergoing ACDF between 2010 and 2014. Updated trend weights were used to assess patient demographics, comorbidities, complications, LOS, discharge disposition and total cost. Multivariate logistic regression was used to determine the odds ratio for risk-adjusted LOS. The primary outcome was the degree to which patient comorbidities or postoperative complications correlated with extended LOS (>3 days). We identified 144,514 patients with 29,947 (20.7%) experiencing an extended LOS (Normal LOS: 114,567; Extended LOS: 29,947). Comorbidities were overall significantly higher in the extended LOS cohort compared to the normal LOS cohort. Patients with extended LOS had a significantly greater proportion of blood transfusion (p < 0.001) and 2-3 vertebral levels fused (p < 0.001). The overall complication rates were greater in the extended LOS cohort (Normal LOS: 7.4% vs. Extended LOS: 44.8%, p < 0.001). The extended LOS cohort incurred $14,489 more in total cost (Normal LOS: $15,486 [11,787-20,623] vs. Extended LOS: $29,975 [21,286-45,285], p < 0.001) and had more patients discharged to non-routine locations (p < 0.001) compared to the normal LOS cohort. On multivariate logistic regression, several risk-factors were associated with extended LOS including: age, male gender, Black and Hispanic race, patient income, insurance, multiple comorbidities, blood transfusion, and number of complications. The odds ratio for extended LOS was 5.15 (95% CI: 4.68-5.67) for patients with 1 complication and 25.54 (95% CI: 20.54-31.75) for patients with >1 complication. Our national cohort study demonstrated multiple patient- and hospital-level factors associated with extended LOS (>3 days) after ACDF for CSM. Specifically, patients with an extended LOS had lower socioeconomic status, higher rate of comorbidities, greater percentage of postoperative complications and non-routine discharges, with greater overall costs. Further investigational studies are necessary to identify quality improvement strategies targeted to better optimizing patients preoperatively and reducing perioperative complications in order to improve quality of patient care and reduce hospital LOS.

Identifiants

pubmed: 32428797
pii: S0303-8467(20)30226-2
doi: 10.1016/j.clineuro.2020.105883
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105883

Informations de copyright

Copyright © 2020 Elsevier B.V. All rights reserved.

Auteurs

Aladine A Elsamadicy (AA)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States. Electronic address: aladine.elsamadicy@yale.edu.

Andrew B Koo (AB)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States.

Megan Lee (M)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States.

Wyatt B David (WB)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States.

Adam J Kundishora (AJ)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States.

Stephanie M Robert (SM)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States.

Gregory A Kuzmik (GA)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States.

Pedro O Coutinho (PO)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States.

Luis Kolb (L)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States.

Maxwell Laurans (M)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States.

Khalid Abbed (K)

Department of Neurosurgery, Yale University School of Medicine, New Haven, CT, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH